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Abstract: Endothelial dysfunction is a systemic pathological state of the endothelium 
characterized by a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading 
to impaired endothelium-dependent vasodilation, as well as disarrangement in vascular wall 
metabolism and function. One of the key factors in endothelial dysfunction is overproduction of 
reactive oxygen species which participate in the development of hypertension, atherosclerosis, 
diabetes, cardiac hypertrophy, heart failure, ischemia-reperfusion injury, and stroke. Because 
impaired endothelial activity is believed to have a major causal role in the pathophysiology of 
vascular disease, hypertension, and heart failure, therapeutic agents which modify this condition 
are of clinical interest. Nebivolol is a third-generation β-blocker with high selectivity for 
β1-adrenergic receptors and causes vasodilation by interaction with the endothelial L-arginine/
nitric oxide pathway. This dual mechanism of action underscores several hemodynamic qualities 
of nebivolol, which include reductions in heart rate and blood pressure and improvements in 
systolic and diastolic function. Although nebivolol reduces blood pressure to a degree similar 
to that of conventional β-blockers and other types of antihypertensive drugs, it may have 
advantages in populations with difficult-to-treat hypertension, such as patients with heart failure 
along with other comorbidities, like diabetes and obesity, and elderly patients in whom nitric 
oxide-mediated endothelial dysfunction may be more pronounced. Furthermore, recent data 
indicate that nebivolol appears to be a cost-effective treatment for elderly patients with heart 
failure compared with standard care. Thus, nebivolol is an effective and well tolerated agent 
with benefits above those of traditional β-blockers due to its influence on nitric oxide release, 
which give it singular hemodynamic effects, cardioprotective activity, and a good tolerability 
profile. This paper reviews the pharmacology structure and properties of nebivolol, focusing 
on endothelial dysfunction, clinical utility, comparative efficacy, side effects, and quality of 
life in general with respect to the other antihypertensive agents.
Keywords: beta-blockers, nebivolol, oxidative stress, endothelial function, cardiovascular 
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Endothelial dysfunction and cardiovascular risk
The endothelium regulates vascular homeostasis by elaborating a number of paracrine 
factors responsible for maintaining normal vascular tone, and blood fluidity, and limiting 
vascular inflammation and smooth muscle cell proliferation.1,2 Unquestionably, nitric 
oxide is considered to be a key contributor to vascular health in many ways, including 
inhibition of platelet aggregation, monocyte adhesion to endothelial cells, and abnormal 
smooth muscle cell proliferation.3,4
Nitric oxide is generated from L-arginine by the action of endothelial nitric oxide 
synthase in the presence of cofactors, such as tetrahydrobiopterin. Once nitric oxide 
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is produced, it diffuses to vascular smooth muscle cells and 
activates guanylate cyclase, which leads to cGMP-mediated 
vasodilatation (Figure 1).5,6 Additionally, nitric oxide is 
involved in several protective functions of the endothelium 
by limiting vascular inflammation, vascular smooth muscle 
proliferation, platelet aggregation, and production of tissue 
factors.6,7 Therefore, modifications of normal endothelial 
physiology result in endothelial dysfunction, which is 
characterized by a decrease in the bioavailability of vasodila-
tors, especially nitric oxide. In agreement with this concept, 
endothelial dysfunction is currently recognized as a risk 
factor for atherosclerosis, representing an integrated index 
of both the overall cardiovascular risk factor burden and the 
sum of all vasculoprotective factors in an individual.7,8
The activation of β-adrenoreceptors on the endothelium 
stimulates nitric oxide synthesis by endothelial nitric oxide 
synthase. Interestingly, it has been demonstrated that 
overexpression of endothelial nitric oxide synthase could 
paradoxically be maladaptive by leading to oxidative stress 
through synthesis of the superoxide anion.9
It is worth mentioning that permanent β-adrenoreceptor 
activation could exacerbate endothelial nitric oxide synthase 
activity and expression although, in turn, it causes endothelial 
nitric oxide synthase uncoupling that would change into a 
source of superoxide anion generation. At the same time, 
there is convincing evidence suggesting that reduced nitric 
oxide bioavailability following sympathetic hyperactivity 
and/or increased plasma catecholamine levels is the major 
contributor to endothelial dysfunction (Figure 2). Production 
of superoxide anions by uncoupled endothelial nitric oxide 
synthase and inflammatory mediator synthesis induced by 
chronic β-adrenergic activation seem to play an essential 
role in the endothelial dysfunction induced by sympathetic 
overflow. Consequently, both mechanisms may be therapeutic 
targets in cardiovascular disease associated with endothelial 
dysfunction and sympathetic hyperactivity.10,11
Pharmacology of nebivolol
Beta-blockers are among the most widely used drugs for 
prevention and treatment of cardiovascular disease.12–15 They 
comprise a varied group of antihypertensive medications, 
including drugs that block the action of epinephrine and 
norepinephrine on both β
1
-adrenergic and β
2
-adrenergic 
receptors, and are thus considered to be nonselective 
(eg, propranolol, which was the first β-blocker introduced 
into clinical practice). Although it is effective in the 
treatment of hypertension, propranolol has major side 
effects associated mainly with its capability of blocking 
β
2
-adrenergic receptors, particularly at the respiratory level 
and also due to its ability to cross the blood–brain bar-
rier.16,17 This has led to the development and introduction of 
second-generation drugs with selective effects on β
1
-cardiac 
receptors and no effects on vasodilation, eg, atenolol and 
metoprolol.18–21 In general, traditional β-blockers have a 
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Figure 1 Synthesis of nitric oxide by endothelial cells. Nitric oxide is produced by the action of endothelial nitric oxide synthase on L-arginine. Several cofactors, including 
tetrahydrobiopterin (BH4) and nicotinamide adenine dinucleotide phosphate, are required to generate this reaction. Endothelial nitric oxide synthase is activated as a 
consequence of the dislodgement of the inhibitor caveolin from calmodulin in response to vasodilator agonists or shear stress. Nitric oxide diffuses to vascular smooth muscle 
and produces relaxation through activation of guanylate cyclase, thus augmenting intracellular cyclic guanosine monophosphate. 
Abbreviations: eNOS, endothelial nitric oxide synthase; NO, nitric oxide; NADPH, reduced nicotinamide adenine dinucleotide phosphate; CaM, calmodulin; GTP, guanosine 
5’-triphosphate; GC, guanylate cyclase; cGMP, cyclic guanosine monophosphate.
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poorer clinical impact compared with other classes of drugs. 
Notably, they have a low impact on quality of life, and a 
negative effect on carbohydrate and lipid metabolism. The 
blockade of β
1
-adrenergic receptors can induce dyslipidemia 
because these receptors participate in the mechanism of 
lipolysis in adipocytes. Thus, pharmacological research on 
this type of drug has continued, seeking a β-blocker with the 
additional characteristic of inducing peripheral vasodilation. 
This line of investigation has led to the development of 
third-generation β-blockers that differ in the mechanisms 
by which they exert vasodilation.
The most studied and used third-generation β-blocker 
with vasodilating effects is carvedilol. Although it is useful 
in the treatment of heart failure, carvedilol antagonizes 
α
1
-adrenergic receptors but has a combined antagonistic effect 
on both β
1
- and β
2
-receptors.22,23 Blockade of β
2
-receptors 
generates side effects such as fatigue and dizziness, thus 
limiting its use. Therefore, the pharmacologic, mechanistic, 
and hemodynamic differences between conventional 
nonvasodilating β-blockers and vasodilating β-blockers 
have important implications, particularly in the treatment 
of complicated hypertension, such as that associated with 
diabetes or the cardiometabolic syndrome. The effects of 
these agents on endothelial dysfunction may be the main 
contributing factor in these differences.
Nebivolol is the third-generation β-blocker with the 
greatest selectivity for cardiac β
1
-adrenergic receptors 
and the highest β
1
-/β
2
-selectivity compared with other 
β-blockers assessed ex vivo, and because it has no effect 
on α-receptors, it is devoid of intrinsic sympathomimetic 
activity.24,25 Given its characteristics, nebivolol reduces 
blood pressure and peripheral vascular resistance and does 
not depress, but rather tends to maintain or improve, left 
ventricular function in healthy subjects and in patients with 
hypertension by increasing cardiac output and stroke volume, 
reducing systemic vascular resistance, and improving 
diastolic function.26–31
Nebivolol also possesses endothelium-dependent arterial 
and venous vasodilator properties that are largely attributed 
to stimulation of nitric oxide production.31 Importantly, 
participation of α-adrenergic receptors in these effects has 
been ruled out, while showing that the mechanism of action 
of nebivolol proceeded through a different mechanism of 
action from that of carvedilol.32,33 The first demonstration of 
this effect was in isolated canine coronary arteries, showing 
that vasodilation mediated by nebivolol is endothelium-
dependent and abrogated by a nitric oxide inhibitor.31 Later, 
various studies corroborated the importance of nitric oxide in 
the vasodilatory action of nebivolol in humans. The venous 
dilation induced by nebivolol was prevented by inhibitors 
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Figure 2 Effect of acute and chronic β-adrenergic activation on endothelial nitric oxide synthase activity, expression, and uncoupling. (A) In normal conditions, basal endothelial 
nitric oxide synthase activity oxidizes L-arginine, generating L-citrulline and nitric oxide at physiological rates which contributes to maintenance of vascular tone in healthy 
vessels. (B) Acute β-adrenergic activation caused by β-adrenoceptor agonists stimulates endothelial nitric oxide synthase activity and could increase release of endothelial 
nitric oxide. (C) Permanently high catecholamine levels could lead to overactivation of β-adrenoceptors, increasing activity and protein expression of endothelial nitric oxide 
synthase. Nevertheless, this condition may lead to uncoupling of endothelial nitric oxide synthase, which produces superoxide anions and peroxynitrite (reactive oxygen species). 
Abbreviations: eNOS, endothelial nitric oxide synthase; NO, nitric oxide; ROS, reactive oxygen species.
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of nitric oxide synthase.32 Similar results were found for the 
arterial circulation.33–35 Treatment with nebivolol was shown 
to be linked to increased activity of the endothelial isoform of 
endothelial nitric oxide synthase, suggesting participation of 
this enzyme in the vasodilating effects of this drug.36 These 
effects were confirmed by the observation that nitric oxide 
production in vascular tissues increases after stimulation with 
nebivolol.37,38 Importantly, this pharmacological aspect of 
nebivolol does not depend on activation of β1 receptors and 
is not shared by other drugs of the same class. The ability of 
nebivolol to enhance or restore nitric oxide-mediated vaso-
dilation in hypertensive patients has important therapeutic 
implications in view of the well established protective 
role of nitric oxide against cardiovascular risk factors, and 
particularly the development of atherosclerosis.39,40
Nebivolol also stimulates nitric oxide production in the 
heart.41 The effects of nebivolol on cardiac production of 
nitric oxide does not depend on inhibition of β
1
-adrenergic 
receptors because cardiac nitric oxide is not induced by 
other drugs of the same functional class. Nebivolol cannot 
evoke nitric oxide production in the heart in the presence of a 
β
3
-adrenergic receptor antagonist. Its actions on cardiac tissue 
are mediated via stimulation of β
3
-adrenenergic receptors to 
release nitric oxide and promote neoangiogenesis.41 Thus, 
the β
3
-adrenergic receptor has emerged as a potential target 
for the treatment of heart disease.42,43 The cardioprotective 
effects of nebivolol may prove particularly beneficial for 
the treatment of ischemic and heart failure diseases via 
preservation of coronary reserve.44 Indeed, recent studies 
have demonstrated that nebivolol as well as two other specific 
β
3
-adrenegic agonists protect against myocardial ischemia-
reperfusion injury via rapid activation of endothelial and 
neuronal nitric oxide synthase and increased nitric oxide 
bioavailability.45
Nebivolol is a racemic mixture containing equal amounts 
of two isomers, ie, d-nebivolol and l-nebivolol (Figure 3). 
Animal and human pharmacological experiments have 
demonstrated that the antihypertensive and hemodynamic 
action of the racemic mixture is superior to that of the 
isomers alone.46–49 The β
1
-blocking effects of nebivolol 
reside in the d-isomer, while the inhibition of exercise-
induced tachycardia is evident with the racemic mixture.49 
The nitric oxide-releasing effect of nebivolol is mainly due 
to its l-enantiomer.46,47 The racemate and its enantiomers 
possess remarkable antioxidant activity that contributes to 
its effect on metabolism of cellular nitric oxide.48 Nebivolol 
also scavenges reactive oxygen species in a receptor-
independent manner by direct interaction with free radicals. 
Nebivolol has been shown to reduce the concentration of 
superoxide anion in endothelial cells.50 This effect has also 
been detected in experimental animal models51–53 and in 
patients.54,55 By scavenging reactive oxygen species, nebivolol 
not only reduces oxidant stress but also augments nitric oxide 
bioavailability. The attenuation of oxidative stress attained 
with the administration of nebivolol is also associated with 
a reduction in peroxynitrites.53,54 Nebivolol has also been 
shown to inhibit NAD(P)H oxidase activity in various 
models of hypertension, including angiotensin II-treated 
rats, spontaneously hypertensive rats, and transgenic rats 
overexpressing renin.52–54 This is another mechanism by 
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Figure 3 Chemical structure of the two isomers of nebivolol as a hydrochloride salt. Nebivolol has four asymmetric centers; the d-isomer refers to (S,R,R,R)-nebivolol and 
the l-isomer to (R,S,S,S)-nebivolol. The enantiomers have unequal potency with regard to β-receptor blocking activity and nitric oxide-mediated vasodilation.
Abbreviation: Mw, molecular weight.
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which the drug may reduce excessive O
2
− production 
and the oxidative stress milieu that typifies hypertension. 
Therefore, the endothelial nitric oxide synthase-stimulating 
and reactive oxygen species-scavenging effects of nebivolol 
act synergistically to provide cardiovascular protection in 
addition to its β
1
-antagonistic action (Figure 4).
Nebivolol causes downregulation of a number of genes 
involved in the inflammatory process, oxidative stress, and 
smooth muscle cell proliferation.55–57 Such antiproliferative 
effects have clear implications in the modulation of  vascular 
structure, including cavernous tissue,58 with obvious inference 
in erectile dysfunction linked to cardiovascular disease.
It has been documented that β-adrenergic antagonists can 
influence platelet aggregation by a mechanism  independent 
of their ability to antagonize beta-adrenoceptors.59–62 A recent 
study in Zucker diabetic fatty fa/fa rats indicate that platelet 
aggregation was significantly reduced by treatment with 
nebivolol in comparison with atenolol.63 In agreement 
with this experimental finding, a study in human platelets 
showed that although nebivolol, propranolol, and carvedilol 
all had an inhibitory effect on both ADP-induced and 
collagen-induced platelet aggregation, nebivolol exhibited 
the greatest inhibition effect on platelet aggregation. The 
mechanism responsible for the inhibitory effect of nebivolol 
appears to involve a nitric oxide-dependent pathway because 
L-arginine augments the inhibitory effects of nebivolol on 
platelet aggregation. Furthermore, the inhibitory effect of 
nebivolol on platelet aggregation is reduced in the presence 
of the nitric oxide synthase inhibitor, N (G)-monomethyl-L-
arginine. Thus, the mechanism by which nebivolol inhibits 
platelet aggregation differs from that of other β-adrenergic 
antagonists by being partially dependent on nitric oxide 
production.62 The beneficial effects of nebivolol on platelet 
activation are more potent than those of other β-blockers, 
such as metoprolol.64 Therefore, decreased platelet activation 
with nebivolol might play a role in reducing thrombotic risk 
in hypertensive patients.
Clinical efficacy and tolerability
Nebivolol has been developed and studied for three basic 
indications, ie, heart failure, arterial hypertension, and 
coronary artery disease. Regarding heart failure, convincing 
information indicates that β-blocker therapy diminishes 
5-year mortality and morbidity by approximately one 
third in heart failure patients, by causing a reduction in 
adrenergic drive, modulation of sympathovagal balance and 
rate variability, and improvement of cardiac performance. 
However, β-blocker therapy has important side effects 
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Figure 4 Mechanisms of action of nebivolol in the cardiovascular system. Antagonism of cardiac β1-adrenergic receptors by nebivolol maintains or improves left ventricular 
function in healthy subjects and in patients with hypertension by decreasing heart rate, increasing cardiac output, and stroke volume. In addition, nebivolol protects health 
by reducing oxidative stress and increasing nitric oxide bioavailability through nonreceptor dependent scavenging of O2
− and β3-adrenergic receptor-dependent inhibition of 
NADPH oxidase and endothelial nitric oxide synthase uncoupling. In the vasculature, nebivolol acts through β3-adrenergic receptors to augment nitric oxide bioavailability 
and exerts a direct scavenging effect, leading to vasodilation and an improvement of endothelial function.
Notes:  stimulation,  inhibition.
Abbreviations: NADPH, reduced nicotinamide adenine dinucleotide phosphate; NOX, NADPH oxidase; eNOS, endothelial nitric oxide synthase; NO, nitric oxide.
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in these patients.65. The major inconvenience is due to 
the negative inotropic and chronotropic effects of these 
 compounds. Notably, while other β-blockers mostly act by 
reducing stroke volume, nebivolol and carvedilol preserve 
left ventricular function, maintain stroke volume and cardiac 
output, produce peripheral vasodilation, and maintain cardiac 
chronotropism during exertion.66–69 Additionally, unlike 
classical β-blockers, some reports indicate that nebivolol has 
a neutral or beneficial effect on hemodynamic parameters, 
such as mean pulmonary artery pressure and pulmonary 
wedge pressure.70,71 The benefits of nebivolol for heart 
failure treatment have been evaluated in SENIORS (Study 
of Effects of Nebivolol Intervention on Outcomes and 
Rehospitalization in Seniors With Heart Failure), where 
more than 2000 patients aged $70 years with a history of 
heart failure (hospital admission for heart failure within 
the previous year or known ejection fraction #35%) were 
randomized to nebivolol (n = 1067) titrated from 1.25 mg to 
10 mg once daily or placebo (n = 1061). The primary outcome 
was a composite of all-cause mortality or cardiovascular 
hospital admission (time to first event), and mean duration 
of follow-up was 21 months. Nebivolol was effective and 
well tolerated in elderly patients with heart failure.72
With respect to the antihypertensive effect of nebivolol, 
various randomized, double-blind, placebo-controlled trials 
have evaluated its efficacy and tolerability. Nebivolol was 
evaluated in a large open-label, 6-week follow-up study of 
6356 patients with mild-to-moderate essential hypertension 
or isolated systolic hypertension, recruited from 2700 
facilities. In this cohort of patients, the efficacy of nebivolol 
was very similar not only as monotherapy, but also as addon 
therapy. Furthermore, 5–10 mg of nebivolol therapy showed 
a mild impact on diastolic blood pressure.73 Consequently, 
this valuable modulation of diastolic blood pressure 
underscores that nebivolol is highly effective, especially in 
patients with isolated systolic hypertension, and has a good 
safety profile.
Interestingly, a multicenter, double-blind, randomized, 
parallel-group, placebo-controlled, dose-ranging study 
(5 mg, 10 mg, 20 mg once daily for 12 weeks) investigated 
the antihypertensive eff icacy and safety of nebivolol 
monotherapy in patients with stage I through stage II 
hypertension.74 Although the outcomes indicated that 
nebivolol was more effective than placebo at such doses, 
analysis of the response rates revealed that once-daily 
nebivolol 5 mg, 10 mg, and 20 mg showed mild differences 
between them (66.0%, 66.8%, and 68.9%, respectively). This 
finding suggests that higher doses of 5 mg do not provide 
substantially better results. Moreover, while the 5 mg and 
10 mg doses were well tolerated, with an overall adverse 
event incidence comparable with that of placebo, the 20 mg 
dose was associated with an increase in adverse events in 
comparison with placebo. In contrast with this observation, 
a recent study in self-identified Hispanic patients with 
stage I–II hypertension who were randomized to receive a 
double-blind treatment (placebo or nebivolol 5–40 mg/day) 
showed comparable adverse effects in both groups.75
When compared with other antihypertensive drugs, 
such as calcium antagonists or other β-blockers, nebivolol 
achieved similar control in blood pressure with fewer side 
effects, especially in elderly subjects. A meta-analysis of 12 
randomized controlled studies showed that nebivolol 5 mg 
achieved similar or better rates of treatment response and 
blood pressure normalization than other drug classes and 
other antihypertensive drugs combined, with tolerability 
similar to that of placebo and significantly better tolerability 
than losartan, calcium antagonists, other β-blockers, and 
all antihypertensive drugs combined.76 The onset of the 
maximal antihypertensive effect of nebivolol takes places 
after 2–8 weeks of therapy, which is intermediate between 
amlodipine (faster) and angiotensin-converting enzyme 
inhibitors (slower).
Unfortunately, large studies in isolated systolic 
hypertension are currently not available. This topic is 
of paramount importance given that recent information 
suggests neutral or comparatively worse effects of 
β-blockers on mortality and morbidity in patients with 
arterial hypertension.77 Consequently, at present, due to the 
lack of sufficient data to support utilization of β-blockers as 
first-line antihypertensive drugs, use of this class of agents 
remains controversial.
Concerning the therapeutic properties for coronary 
artery disease, nebivolol, as a third-generation β-blocker, 
has a vasodilating capacity and improves hyperemic 
coronary blood flow. This occurs as a result of a decline in 
minimal resistance, which can be assigned to α-adrenergic 
blockade and/or to a nitric oxide-mediated effect. Hence, this 
therapeutic action clearly has a positive effect in patients with 
coronary artery disease. Interestingly, in animal models of 
experimental ischemia and reperfusion injury, nebivolol has 
been shown to have protective effects.78 Moreover, in humans, 
it has been demonstrated that treatment with nebivolol is 
more effective in improving exercise tolerance and time 
to onset of angina during exercise testing when compared 
with atenolol.79 In agreement with this, because nebivolol 
improves coronary microvascular function, a secondary 
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benefit of improvement in left ventricular function could 
be expected in those patients with angina pectoris or silent 
ischemia. However, unfortunately, information regarding the 
impact of nebivolol on mortality and morbidity in coronary 
artery disease is not available at present.
Comparative impact  
on cardiovascular risk
Experimental data in animals with metabolic syndrome 
indicate that nebivolol has an actual protective role, 
not only in cardiovascular structures but also in renal 
tissue, in comparison with atenolol.58,63,80 Evaluation of 
immunoexpression of plasminogen activator inhibitor-1 and 
cell adhesion molecules, such as VCAM-1 and PECAM-1, in 
the vascular wall of diabetic rats which received nebivolol for 
6 months showed favorable modification of these prothrom-
botic and vascular inflammatory markers when compared 
with atenolol.63 Because nitric oxide regulates the expression 
of cell adhesion molecules, and increased levels of nitric 
oxide are associated with decreased expression of adhesion 
molecules, it would be understandable that treatment with 
nebivolol causes an actual profit on vascular structures in a 
hyperlipidemic and hyperglycemic environment.
In clinical studies, it has been reported that whereas 
atenolol considerably increased cholesterol and triglyceride 
levels, nebivolol decreased serum triglycerides, with a 
favorable effect on the cholesterol profile.81 Persistent 
hypertriglyceridemia has a deleterious effect on the β-cell 
in the pancreas (lipotoxicity), and this, together with the 
metabolic environment of diabetes, may contribute to 
accelerating the negative effect on islet function. Therefore, 
a favorable modification in the lipid status by nebivolol may 
preserve the pancreatic β-cell metabolism in this scenario. In 
addition, because insulin resistance is commonly associated 
with endothelial dysfunction and exposure of vascular 
endothelium to high circulating levels of lipids and glucose 
is accompanied by reduced nitric oxide availability, the most 
likely mechanism for the differences between nebivolol 
and atenolol with respect to metabolic profile would be the 
ability of nebivolol to increase nitric oxide bioavailability, as 
demonstrated in animals and hypertensive patients.82
Recently, the antihypertensive efficacy and effects of 
nebivolol alone and in association with hydrochlorothiazide 
on glucose and lipid metabolism in hypertensive patients 
were assessed. An improvement in glucose metabolism 
was noted with nebivolol alone, ie, a significant reduction 
in homeostasis model assessment–insulin resistance, and 
adjunctive use of hydrochlorothiazide blunted this reduction. 
No significant changes in the lipid profile were noted with 
nebivolol, either alone or in combination therapy.83 This 
information is particularly relevant to the management of 
patients resistant to monotherapy in order to optimize blood 
pressure control without a negative impact on glucose and 
lipid profiles.
The effects of nebivolol and influence of diabetes 
mellitus and hyperglycemia on the prognosis in elder patents 
($70 years) with heart failure was recently reported in a 
subanalysis of SENIORS.84 The conclusion was that elder 
patients with heart failure and diabetes mellitus had a worse 
prognosis. Nebivolol was less effective in patients with 
diabetes and heart failure than in those with heart failure 
but without diabetes.
Patient-focused perspectives
Quality of life is an increasingly important tool in assessing 
treatment effects and allocating resources to where they are 
most effective. Given that the benefits of antihypertensive 
treatment and therapy for heart failure are long-term and any 
discomfort of having to take daily medication is immediate, 
a therapeutic agent with positive overall effects on quality of 
life should have as little negative influence on patients’ every-
day lives as possible. The greatest impact on quality of life 
was reported for cardiovascular drugs with side effects, such 
as reduced exercise capacity, emotional distress, alterations 
in sexual function, insomnia, tiredness, and depression.
A trial investigating three β-blockers showed that 
bisoprolol, but not nebivolol or carvedilol, decreased 
nocturnal release of melatonin, a phenomenon that may 
cause sleep disturbances.85 This study also showed that 
carvedilol slightly decreased quality of life, whereas 
nebivolol and bisoprolol had no influence, suggesting 
that different β-blockers exert different clinically relevant 
effects. In agreement with this, data from a prospective, 
randomized, open-label study on the impact of β-blockers on 
sleep in patients with mild hypertension indicate significant 
differences between nebivolol versus metoprolol.86 Eligible 
patients were administered the Pittsburgh Sleep Quality Index 
questionnaire by a blinded interviewer and were randomized 
to receive metoprolol or nebivolol. Interestingly, the patients 
treated with nebivolol showed improved sleep parameters 
whereas those treated with metoprolol showed detrimental 
effects. Considering that sleep is an important component 
of quality of life, it should be carefully taken into account 
during any therapeutic intervention.
It is widely accepted that administration of traditional 
β-blockers is one of the leading causes of drug-related 
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erectile dysfunction. However, recent data indicate that 
patients treated with nebivolol obtained higher scores in every 
parameter of the International Index of Erectile Dysfunction 
questionnaire. Furthermore, treatment with nebivolol was 
associated with a lower prevalence of erectile dysfunction in 
this study.87 In another double-blind, randomized, parallel-
group study in more than 300 patients with hypertension, 
when nebivolol was compared with losartan, the effect on 
sexual function did not differ between these two treatments 
after 6 weeks of monotherapy.88
Concerning physical activity, when evaluated in the long 
term, nebivolol has been demonstrated to improve exercise 
capacity, especially in patients with hypertension and heart 
failure, at a similar level to carvedilol.89 However, in a recent 
randomized, placebo-controlled trial, exercise performance, 
evaluated by cardiopulmonary exercise, was better preserved 
with nebivolol than with carvedilol under acute exposure to 
high altitude (4559 m) hypoxia in healthy subjects.90
Conclusion
Although nebivolol reduces blood pressure to a degree 
similar to that of conventional β-blockers and other types 
of antihypertensive drugs, it may have advantages in 
populations with difficult-to-treat hypertension, such as 
diabetics, obese patients, and the elderly, in whom nitric 
oxide-mediated endothelial dysfunction may be more 
pronounced. Consequently, with the aim to achieve the best 
“tailor made” treatment for a patient with hypertension and 
heart failure together with other comorbidities, selection of 
the most suitable β-blocker is of paramount importance.
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